-3.18 | -7.78%
| Price and Volume | |
|---|---|
| Recent Price | 37.70 |
| 52 Week High | 42.80 |
| 52 Week Low | 24.85 |
| Avg. Daily Vol. (Mil) | 0.33 |
| Beta (3 year) | 1.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,385.43 |
| Shares Out (Mil) | 36.75 |
| Float (Mil) | 36.16 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.54 |
| Total Debt / Equity | 0.58 |
| Valuation Ratios | |
| Price Earnings | 25.10 |
| Price/Sales | 1.44 |
| Price/Book | 2.36 |
| Price/Cash Flow | 20.00 |
| Per Share Data | |
| Earnings | 1.50 |
| Sales | 26.25 |
| Book Value | 15.99 |
| Cash Flow | 1.89 |
| Business Summary | |
|---|---|
| Par Pharmaceutical Companies, Inc, is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. | |
| General Information | |
| 300 Tice Boulevard
Woodcliff Lake, NJ 07677 |
|
| www.parpharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 819 | |
| CEO: Patrick G. Lepore | |
| Short Interest | |
| Current Month (Mil) | 1.47 |
| Previous Month (Mil) | 1.34 |
| Short Interest Ratio (Days) | 4.60 |
| Management Effectiveness | |
| Return on Equity | 5.80 |
| Return on Assets | 2.70 |
| Return on Investments | 3.80 |
| Profitability | |
| Gross Margin | 42.50 |
| EBIT Margin | 9.10 |
| Profit Margin | 3.50 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 16.73 |
Oil *
104.61
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.58 |
10 Yr
1.67%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-3.35%
|
Data delayed 20 minutes |
Connect with TheStreet